(PharmaNewsWire.Com, January 05, 2018 ) According to the report, the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is published by the Market Data Forecast. The industry has been expected to reach USD 12.43 billion by 2020 from USD 8.08 billion in 2015, growing at a CAGR of 9.00% during the forecast period 2015-2020.
Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (above12 years age) as compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of nervous system that led to attention deficit and hyperactivity/impulsiveness condition. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).
Increasing advancements in medical field, growing number of researches in neurosciences, rising awareness about mental illness among people, and increasing focus of biotechnology & pharmaceutical companies to develop the innovative therapeutics for ADHD are driving the growth of global attention deficit hyperactivity disorder therapeutics Industry. However, high cost of the ADHD medications, improper reimbursement policies, and side effects related to ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes) are restraining the growth of global attention deficit hyperactivity disorder therapeutics Industry.
•Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) • Industry Segmentation o Treatment By Medication o Treatment By Psychotherapy o Treatment By Education or Training •Geographical Analysis •Pipeline Product Analysis •Strategic Analysis •PESTLE analysis •Porter’s Five analysis
Global attention deficit hyperactivity disorder (ADHD) therapeutics Industry is segmented based on medication, psychotherapy, and education or training. Medication involves stimulants and non-stimulants. Medication by stimulants comprises of amphetamines, methylphenidate, dextroamphetamine, and dexmethylphenidate, whereas medication by non-stimulants comprises of atomoxetine, bupropion, and guanfacine. Psychotherapy involves behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy. Education or training involves parent management training, social skills training, and school-based interventions.
On the basis of geographical region the global attention deficit hyperactivity disorder (ADHD) therapeutics Industry is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America commanded the highest share of 36.0% of the global attention deficit hyperactivity disorder (ADHD) therapeutics Industry in 2015, whereas Asia-Pacific is estimated to grow at the highest CAGR of 12.30% during the forecast period 2015-2020.
The key players in global attention deficit hyperactivity disorder (ADHD) therapeutics Industry such as, Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.)
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
